Improving patient access to life-enhancing medications

Mayne Pharma Group Limited is pleased to announce the completion of the sale of Metrics Contract Services (Metrics) to Catalent Pharma Solutions, Inc. for US$475 million (approximately A$722 million at current exchange rates).

Mayne Pharma Group Limited is pleased to announce it has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer and Managing Director effective 1 October 2022. This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr David Petrie, has accepted an invitation to join the Board of Mayne Pharma, effective 1 September 2022.

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, we reported annual revenue growth for the first time in five years. Excluding retail generics, the remaining businesses which represent more than 80% of reported gross profit grew 27% on the prior corresponding period (pcp).

Mayne Pharma Group Limited advises that Chief Executive Officer (CEO) Scott Richards has announced his intention to retire following a decision by the Board to relocate the CEO role to the US on a permanent basis. Mr Richards is unable to make this commitment and wants to return to Australia for personal reasons.

Mayne Pharma today announced that it has entered into an agreement with Catalent to sell Metrics Contract Services for a total cash consideration of US$475 million (~A$679 million)